Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin
Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin
This is a randomized double-blinded study examining the effect of topical Acetyl
 Hexapeptide-8 AH8) for improving the cosmetic appearance and experience of oily skin.
The purpose of this randomized double-blinded study is to investigate whether topical Acetyl
 Hexapeptide-8 can improve oily skin. Up to 15 adult subjects will be recruited. Each half of
 the face will randomized to receive either topical treatment with AH8 10% Lotion formulated
 in Cetaphil® Moisturizing Facial Lotion or the placebo vehicle treatment consisting of
 Cetaphil® Moisturizing Facial Lotion only, at twice daily application for 4 weeks.

 The study consists of a total of 3 sessions: baseline visit, and at 2 weeks and 4 weeks for
 follow up assessment. Subjects will also be asked to complete an Oily Skin Self-Assessment
 Scale (OSSAS) and an Oily Skin Impact Scale (OSIS) survey at the first session. They will be
 filling out two OSSAS surveys (one for each side of the face) at the second and third
 sessions. The OSSAS survey includes subjective assessment of four components of oily skin:
 visual, blotting, tactile, and sensation. At each visit, the cosmetic appearance the facial
 skin will be scored clinically by a dermatologist using a validated 3-point scale for shine
 (1 = high, 2, moderate or 3 = low), and oiliness (1 = normal, 2 = easily visible or 3 =
 extensive) 16. High-resolution digital photographs of the facial skin with the use of
 photography and facial analysis instrumentation will be taken at baseline and at each visit
 to document facial appearance and for image analysis of shine level. Sebum of the left and
 right cheeks will be measured by a sebumeter to correlate to the oily appearance noted on the
 high resolution facial photographs.
Inclusion Criteria:

 -  Subjects over the age of 18

 Exclusion Criteria:

 -  Recent intradermal botulinum neurotoxin injection within the last 6 months.

 -  Known hypersensitivity to AH8

 -  Ablative resurfacing procedures to the face within 6 months of the study initiation

 -  Report of pregnancy or breastfeeding

 -  Use of immunosuppressive drugs